|Bid||7.51 x 800|
|Ask||7.52 x 39400|
|Day's Range||7.50 - 7.64|
|52 Week Range||4.05 - 12.52|
|Beta (3Y Monthly)||2.87|
|PE Ratio (TTM)||34.77|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The fuel for this Southeast Asian country is its export economy and young workforce. But while it may steal some production from China in a trade war, a faltering global economy will hurt. And stocks are pricey.
Operating results for the largest pot stock in the world are due out next week -- here's what you need to know.
If you have doubts that cannabis is on its way from illegal to industrial, take a look inside Cresco Labs’ custom built, 43-thousand square-foot production facility in Joliet, Illinois.
At first glance, cannabis and cryptocurrencies seem to have a lot in common. Both comprise highly speculative markets subject to exuberant highs and crushing lows. The legality and regulation of each has languished in the gray. And to many mainstream investors, both have failed to shake synonymy with the black market.
Marijuana stocks got clobbered last month, and their performances are a mixed bag so far in June.
While vital to the long-term success of the cannabis industry, don't overestimate the near-term impact of pushing into overseas markets.
Aphria stock was flying high Friday morning after the marijuana firm announced it was among four Canadian growers to partner with San Francisco-based PAX Labs for cannabis vaporizers.
Canopy Growth is doubling down on hemp after moving forward with investing up to $150 million to cultivate in New York state. Now, up to seven states could follow.
Aurora Cannabis: June Ratings Update(Continued from Prior Part)ValuationsAurora Cannabis (ACB) has traded at a premium valuation compared to its peers since the beginning of this year. Currently, the stock is trading at a forward EV-to-sales
Aurora Cannabis: June Ratings UpdateAurora CannabisOver the past two few months, Aurora Cannabis (ACB) stock has seen an increase in the number of analysts providing coverage on the stock. In June, one more analyst initiated coverage on the stock,
Just how high can CBD sales climb? That's the key question facing companies and regulators as cannabis goes mainstream.